News

March 30, 2020
Data from pooled analysis of clinical trials supports alternate approach WASHINGTON (Mar 29, 2020) - Patients undergoing heart bypass surgery lived longer and had better outcomes when surgeons used a segment of an artery from their arm, called the radial artery, instead of a vein from their leg, called the saphenous vein, to create a second bypass, according to resear
March 30, 2020
TWILIGHT subanalysis finds benefit for subgroup of high-risk patients WASHINGTON (Mar 29, 2020) - Patients with complex heart disease who stopped taking aspirin three months after the insertion of one or more coronary stents and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or
March 30, 2020
No increase in bleeding, heart attack or stroke in TWILIGHT trial subanalysis WASHINGTON (Mar 29, 2020) - Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse e
March 30, 2020
Finding driven by reduced risk of major bleeding in monotherapy group WASHINGTON (Mar 29, 2020) - Patients with acute coronary syndrome (ACS) who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for nine months had fewer episodes of bleeding and no increase in heart attacks, stroke
March 30, 2020
Data showed that 87 patients treated with a stent (29.8%) and 72 treated with bypass surgery (24.7%) had died, had a heart attack or stroke, or needed a second procedure to unblock the same artery, a difference that was not statistically significant.
March 29, 2020
No survival differences seen in randomized, placebo-controlled trial WASHINGTON (Mar 29, 2020) - Among patients who had an out-of-hospital cardiac arrest, intravenous sodium
March 29, 2020
DOAC more effective in lowering risk of post-procedure VTE without increasing bleeding risk WASHINGTON (Mar 29, 2020) - The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembol